The Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage (ANNEXA-I) trial included a “usual care” arm with PCC use, highlighting that andexanet significantly reduced hematoma expansion compared with usual care but was associated with an increased ischemic stroke risk (6.5% vs 1.5%) [33]. This evidence concerns the gene F10 and ischemic stroke.